Inventaire - teman dan komunitas anda adalah perpustakaan terbaik

Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab

pengarang

Udupi A Ramagopal

Steven C. Almo

Jeffrey B Bonanno

diterbitkan dalam: Proceedings of the National Academy of Sciences of the United States of America

tanggal publikasi: 2017-05-08

bahasa: Inggris

subyek utama: Ipilimumab, cytotoxic T-lymphocyte associated protein 4, Imunoterapi

Cites articles 58

Date

Judul

Pengarang

2016-03-03

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Sunil Kumar Saini, Richard Mitter, Nicolai J Birkbak, Sine Reker Hadrup, Nicholas McGranahan, Charles Swanton, Sergio A Quezada, Dirk Schadendorf, Crispin T Hiley, Levi A Garraway, Jedd D Wolchok, Matthew D Hellmann, Mariam Jamal-Hanjani, Seema Shafi, Teresa Marafioti, Ayse U Akarca, Karl S Peggs, Nirupa Murugaesu, Taha Merghoub, Rikke Lyngaa
2016-03-02

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016-02-05

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
2015-09-10

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab

Bartosz Chmielowski, Antoni Ribas, Luis H Camacho
2015-09-01

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

Alexandria P. Cogdill, Carl H. June
2015-09-01

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity

Dean A. Lee, M Helen Huls, Richard E Champlin
2015-04-27

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

Monika Kusio-Kobialka
2015-04-20

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Caroline Robert, Jedd D Wolchok, F Stephen Hodi
2015-06-25

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Adil Daud, Christian U Blank
2015-02-09

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Dirk Schadendorf, Caroline Robert, Tai-Tsang Chen, Jedd D Wolchok, F Stephen Hodi
2015-09-01

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Jedd D Wolchok, F Stephen Hodi
2014-10-30

Structure and cancer immunotherapy of the B7 family member B7x

Vladimir Vigdorovich, Murali Janakiram, Joseph Sparano, Steven C. Almo
2014-07-08

Considerations for combined immune checkpoint modulation and radiation treatment

Steven C. Almo
2013-08-26

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

James P. Allison, Sergio A Quezada, Jedd D Wolchok, Jeffrey Ravetch
2013-06-02

Nivolumab plus ipilimumab in advanced melanoma

Mario Sznol, Jedd D Wolchok
2013-01-01

The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors

Licia Rivoltini, Matteo Bellone, Arianna Calcinotto, Angelo De Milito, Stefano Fais
2013-01-07

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

Grant McArthur, Michele Maio, Richard F. Kefford, Paul Lorigan, Antoni Ribas, Jacob Schachter
2013-01-03

Acidity generated by the tumor microenvironment drives local invasion

Heather H Cornnell, Robert J Gillies, Yoganand Balagurunathan, Robert Gatenby
2013-12-01

Breakthrough of the year 2013. Cancer immunotherapy

Jennifer Couzin-Frankel
2013-04-07

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells
2013-04-08

Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

Bruce D. Cheson
2013-09-03

Acidic extracellular microenvironment and cancer
2012-06-29

Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells

Kesley Attridge, David M Sansom, Claire Manzotti
2012-03-22

The blockade of immune checkpoints in cancer immunotherapy

Drew M Pardoll
2012-07-02

Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans,Cutting edge: CTLA-4 on effector T cells inhibits in trans

James P. Allison
2011-12-21

Cancer immunotherapy comes of age

George Coukos
2011-06-01

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

Steven Rosenberg, Howard L. Kaufman, Francesco Marincola, Patrick Hwu
2011-04-29

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

Satdip Kaur, Kesley Attridge, Claire Manzotti, Clare E Futter, Graham Anderson, David M Sansom
2011-04

Overview of the CCP4 suite and current developments

Paul Emsley, Kevin Cowtan, Randy Read, Keith S Wilson, Airlie McCoy, Harold R Powell
2011-02-25

Rigid-body Ligand Recognition Drives Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Receptor Triggering

John E. Ladbury, David Ian Stuart, Christine Orengo, Benoit H Dessailly
2010-08-19

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Dirk Schadendorf, Paul Lorigan, Christian H. Ottensmeier, Caroline Robert, Jedd D Wolchok, F Stephen Hodi
2010-01

Molecular replacement with MOLREP

Alexey Teplyakov

Artikel - wd:Q30274619

Selamat datang di Inventaire

perpustakaan teman-teman dan komunitas anda

pelajari lebih lanjut